Yap TA - Search Results

1

Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics.

Yap TA, Workman P. Yap TA, et al. Annu Rev Pharmacol Toxicol. 2012;52:549-73. doi: 10.1146/annurev-pharmtox-010611-134532. Annu Rev Pharmacol Toxicol. 2012. PMID: 22235862 Review.

2

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.

Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Yap TA, et al. Curr Opin Pharmacol. 2008 Aug;8(4):393-412. doi: 10.1016/j.coph.2008.08.004. Epub 2008 Aug 27. Curr Opin Pharmacol. 2008. PMID: 18721898 Review.

3

Beyond chemotherapy: targeted therapies in ovarian cancer.

Yap TA, Carden CP, Kaye SB. Yap TA, et al. Nat Rev Cancer. 2009 Mar;9(3):167-81. doi: 10.1038/nrc2583. Nat Rev Cancer. 2009. PMID: 19238149 Review.

4

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

Carden CP, Sarker D, Postel-Vinay S, Yap TA, Attard G, Banerji U, Garrett MD, Thomas GV, Workman P, Kaye SB, de Bono JS. Carden CP, et al. Among authors: yap ta. Drug Discov Today. 2010 Feb;15(3-4):88-97. doi: 10.1016/j.drudis.2009.11.006. Epub 2009 Dec 2. Drug Discov Today. 2010. PMID: 19961955 Review.

5

AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.

Grimshaw KM, Hunter LJ, Yap TA, Heaton SP, Walton MI, Woodhead SJ, Fazal L, Reule M, Davies TG, Seavers LC, Lock V, Lyons JF, Thompson NT, Workman P, Garrett MD. Grimshaw KM, et al. Among authors: yap ta. Mol Cancer Ther. 2010 May;9(5):1100-10. doi: 10.1158/1535-7163.MCT-09-0986. Epub 2010 Apr 27. Mol Cancer Ther. 2010. PMID: 20423992 Free PMC article.

6

Envisioning the future of early anticancer drug development.

Yap TA, Sandhu SK, Workman P, de Bono JS. Yap TA, et al. Nat Rev Cancer. 2010 Jul;10(7):514-23. doi: 10.1038/nrc2870. Epub 2010 Jun 10. Nat Rev Cancer. 2010. PMID: 20535131 Review.

7

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.

Yap TA, Walton MI, Hunter LJ, Valenti M, de Haven Brandon A, Eve PD, Ruddle R, Heaton SP, Henley A, Pickard L, Vijayaraghavan G, Caldwell JJ, Thompson NT, Aherne W, Raynaud FI, Eccles SA, Workman P, Collins I, Garrett MD. Yap TA, et al. Mol Cancer Ther. 2011 Feb;10(2):360-71. doi: 10.1158/1535-7163.MCT-10-0760. Epub 2010 Dec 29. Mol Cancer Ther. 2011. PMID: 21191045 Free PMC article.

8

Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.

Yap TA, Olmos D, Molife LR, de Bono JS. Yap TA, et al. Expert Opin Investig Drugs. 2011 Sep;20(9):1293-304. doi: 10.1517/13543784.2011.602630. Epub 2011 Jul 22. Expert Opin Investig Drugs. 2011. PMID: 21777167 Review.

9

HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.

Yap TA, Sandhu SK, Alam SM, de Bono JS. Yap TA, et al. Curr Drug Targets. 2011 Dec;12(14):2045-58. doi: 10.2174/138945011798829348. Curr Drug Targets. 2011. PMID: 21777195 Review.

10

AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.

Yap TA, Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, de Haven Brandon AK, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, Workman P, Thompson NT, Garrett MD. Yap TA, et al. Clin Cancer Res. 2012 Jul 15;18(14):3912-23. doi: 10.1158/1078-0432.CCR-11-3313. Epub 2012 Jul 10. Clin Cancer Res. 2012. PMID: 22781553

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

249 results

Search Page

Filters